"Medicare and Medicaid Expand Coverage for Heart Benefits of Obesity Drug Wegovy"

Novo Nordisk's weight-loss medication, Wegovy, has been approved for coverage by Medicare and Medicaid for individuals using it to manage heart-related conditions, following its demonstrated health benefits in reducing the risk of heart disease. This decision is expected to impact the market estimates for the drug, reinforcing its demand, while also highlighting the ongoing issue of supply shortages. Additionally, other pharmaceutical companies are also conducting studies on similar health conditions, indicating a continued focus on expanding the potential uses of these medications.